This fundie is underweight CSL (ASX: CSL) shares. Here’s why.

What’s in-store for the Aussie biotech giant in 2021?
The post This fundie is underweight CSL (ASX: CSL) shares. Here’s why. appeared first on The Motley Fool Australia. –

CSL shares have had an up-and-down start to the year. Shares in the Aussie biotech company are down 1.9% year-to-date and closed at $279.52 per share on Tuesday.

Despite falling 8% in the last month, CSL still boasts a $127.2 billion market capitalisation. That makes it one of the largest shares in the S&P/ASX 200 Index (ASX: XJO) and a perennial index mover and shaker.

But one leading fundie doesn’t have a great outlook for CSL shares in 2021. Yarra Capital Management recently released a May 2021 investment and portfolio update for its Yarra Australian Equities Fund and CSL was notably “underweight”.

Why one leading fundie isn’t bullish on CSL shares

CSL was noted as one of the key detractors to portfolio performance in the fund’s most recent update. That’s despite Yarra Capital noting that CSL outperformed as many expected the company to benefit from a re-opening of the US economy.

Foot traffic at CSL’s collection centres reportedly increased in recent weeks but that hasn’t changed Yarra Capital’s position. The fund remains underweight the Aussie biotech share, based on its forward valuations.

According to the update, CSL shares are trading at a 44.2 times price to earnings (P/E) ratio and 29.7 times enterprise value to earnings before interest, tax, depreciation and amortisation (EV/EBITDA) multiples on a forward basis. In the fund’s view, this relative valuation captures its earnings outlook for CSL right now.

However, Yarra did note the growth outlook for CSL’s key plasma products remains “robust”. Although it doesn’t look like it’ll be snapping up more CSL shares anytime soon.

Foolish takeaway

CSL shares have been under pressure in the last month or so. Shares in the Aussie biotech have slumped while the benchmark ASX 200 index has edged 0.6% lower.

While investors hope for a change in fortunes for the Aussie biotech’s valuation, the Yarra Australia Equities Fund looks content to avoid CSL for the time being.

The post This fundie is underweight CSL (ASX: CSL) shares. Here’s why. appeared first on The Motley Fool Australia.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.

*Returns as of May 24th 2021

More reading

Is the Appen (ASX:APX) share price an opportunity?
Why the CSL (ASX:CSL) share price has trailed the ASX 200 by 23% in the last year
5 things to watch on the ASX 200 on Wednesday

ASX 200 flat, Select Harvest jumps, Nearmap soars

Ansarda (ASX:AND) share price surges on record quarter

Motley Fool contributor Ken Hall has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!